Diabetic Retinopathy News and Research

RSS
In the initial stages, people with diabetic retinopathy may not notice their vision changing. Diabetics sometimes experience rapid changes in blood sugar that can temporarily cause blurry vision even when retinopathy is not present. If a person notices a few specks or spots floating in his visual field, this may mean he has developed proliferative diabetic retinopathy, the growth of abnormal new blood vessels on the retina and optic nerve. High blood sugar levels have been linked in studies to retinal blood vessel abnormalities. Blurred vision may occur when the macula--the small area at the center of the retina--swells as it fills with fluid that has leaked from retinal blood vessels. Because damage to the eye often develops slowly, early detection of diabetes and control of blood sugar through diet and medications can make a crucial difference in saving vision.

Effective diabetic retinopathy treatments include laser photocoagulation for early to moderate stages and a microsurgery called vitrectomy for repair of eyes with extensive damage. Injectable and oral medications that act on abnormal blood vessels to control diabetic retinopathy before vision loss occurs are now in development. Early detection would be key to the effectiveness of these treatments, also.
Thrombogenics issues business update and half year results

Thrombogenics issues business update and half year results

Researchers find connection between eye disease and arginase

Researchers find connection between eye disease and arginase

Stopping type 1 diabetes damage with vitamin C

Stopping type 1 diabetes damage with vitamin C

Diabetics who have retinopathy should also be screened for obstructive sleep apnea

Diabetics who have retinopathy should also be screened for obstructive sleep apnea

Protein kinase JNK1 identified as treatment target for retinopathy in premature babies

Protein kinase JNK1 identified as treatment target for retinopathy in premature babies

Columbia University licenses retinal imaging technology to PCAsso Diagnostics

Columbia University licenses retinal imaging technology to PCAsso Diagnostics

Growth factor TGF-beta helps maintain health of retinal blood vessels

Growth factor TGF-beta helps maintain health of retinal blood vessels

SARcode announces results of phase 1 trial of SAR 1118 ophthalmic solution in healthy adult subjects

SARcode announces results of phase 1 trial of SAR 1118 ophthalmic solution in healthy adult subjects

Diabetic retinopathy more prevalent in South Asians and occurs earlier

Diabetic retinopathy more prevalent in South Asians and occurs earlier

New class of smart prosthetic implants may help prevent blindness

New class of smart prosthetic implants may help prevent blindness

Shining light on diabetic retinopathy

Shining light on diabetic retinopathy

New technology could save vision of millions

New technology could save vision of millions

Protease inhibitor found to aid diabetic retinopathy treatment

Protease inhibitor found to aid diabetic retinopathy treatment

Cases of major eye disease projected to increase among diabetics

Cases of major eye disease projected to increase among diabetics

Ellex Medical Lasers announces results of retina regeneration therapy

Ellex Medical Lasers announces results of retina regeneration therapy

Research targets diabetes-related eye conditions

Research targets diabetes-related eye conditions

Diabetics more likely to lose their vision

Diabetics more likely to lose their vision

Visual impairment more common in people with diabetes

Visual impairment more common in people with diabetes

First genetic research model of retina receptors

First genetic research model of retina receptors

Data Safety Monitoring Board supports continuation of trial of Iluvien for diabetic macular edema

Data Safety Monitoring Board supports continuation of trial of Iluvien for diabetic macular edema

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.